Desmopressin in Acquired von Willebrand Syndrome caused by Aortic Valve Stenosis - Desmopressin in Acquired von Willebrand Syndrome
- Conditions
- Acquired type 2A von Willebrand syndrome is common in patients with severe aortic valve stenosis (AS). It originates from the mechanical obstruction of blood flow and the consecutive proteolysis of von vWF (von Willebrand factor) as it passes through the stenotic valve. Type 2A von Willebrand syndrome (vWS) is characterized by the loss of the largest multimers of vWF, which are the most effective in platelet-mediated hemostasis under conditions of high shear stress.
- Registration Number
- EUCTR2005-004559-36-AT
- Lead Sponsor
- Abteilung für Herz-Thorax-Gefäß Anästhesie & Intensivmedizin (HTG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 60
?Signed informed consent form before trial-related activities
?Patients undergoing elective bioprosthetic aortic valve replacement
?Left ventricular ejection fraction > 40%
?Patients aged ? 18 and ? 90 years
?Prolonged closure time PFA-100 (ADP)> 170 (s).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
?Participation in another clinical trial
?Incompetence to give consent (language and comprehension)
?Active endocarditis
?Association with coronary artery disease
?Multivalvular disease
?Antiplatelet treatment that could not be stopped 7 days before surgery
?Pregnancy or child-bearing potential
?BMI > 40 kg/m2
?Serum creatinine > 1.5 mg/dL
?Known hypersensitivity towards DDAVP
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method